Memorial Sloan Kettering Medical Oncologist Komal Jhaveri

Komal Jhaveri, MD, FACP

Breast Medical Oncologist & Early Drug Development Specialist

My Role at MSK

Areas of Expertise

My Specialties

  • Breast Cancer
  • Early-Phase Clinical Trials

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Section Head, Endocrine Therapy Research Program
  • Clinical Director, Early Drug Development Service
  • Patricia and James Cayne Chair for Junior Faculty
Get To Know Me

I am a medical oncologist dedicated to caring for people with breast cancer. Each year, I provide care to approximately 300 people across Memorial Sloan Kettering Cancer Center (MSK) in Manhattan and the David H. Koch Center for Cancer Care.

I am fortunate to have a career that I’m passionate about and that allows me to help so many people, both in the clinic and through research that may impact cancer care in the future.

Read more

When patients first meet with me, I take time to address their concerns about their diagnosis and answer their questions regarding treatment and prognosis. I try to lessen their anxiety and earn their trust so they feel comfortable in my presence. It is important to me that patients know they are in good hands with me, and with their experienced clinical care team, which includes a registered nurse, a nurse practitioner, or a physician assistant. When needed, I also refer patients to a social worker, a support group, and/or integrative medicine services. These resources can help patients cope and improve their overall wellbeing.

Some people may wonder if they did something wrong or are somehow responsible for developing cancer, but I reassure them that it is not their fault. Whether a person has early-stage disease or their cancer has metastasized (spread), I help them focus on what we can do and encourage them with information about research developments and new treatment options that may benefit them. We talk about exciting advances in the field that have led to our ability to cure patients, achieve long-term remissions, and prolong survival while maintaining quality of life, even for those with late-stage disease. In instances when patients are not able to receive treatment or do not wish to pursue therapy, I help them navigate those decisions.

Medical oncology is a unique subspecialty because it allows doctors and patients to cultivate close relationships and, in most cases, requires continuity of care. I chose this field not only because I wanted to understand the science and biology behind what drives cancer while working to find a cure or ways to improve patient outcomes, but also to develop long-term relationships with patients and their families. Patients let me into the most intimate aspects of their lives; I am privileged to be able to celebrate their happy moments and, in other instances, to guide them and their loved ones through very difficult times.

At MSK, I conduct translational research in collaboration with my laboratory colleagues to shepherd our findings from the lab to the clinic. Through my research, I aim to accelerate the development of new treatments and improve outcomes for people with breast cancer. Our latest work involves the use of acquired biospecimen (cell-free DNA and tumor) analyses and imaging studies to identify and understand biomarkers indicating response or resistance to breast cancer treatment.

As the section head for the Endocrine Therapy Research Program, I manage the clinical trial portfolio for hormone receptor-positive HER2-negative/low breast cancer. I am currently involved with trials evaluating novel PI3K inhibitors, new endocrine drugs used alone or in combination with other drugs, and antibody drug conjugates, among other investigational therapies. I also serve as the Clinical Director for the Early Drug Development Service. This work positions me as the principal investigator for many exciting phase 1 trials led by this service.

Outside of work, I enjoy traveling and playing board games with my family. I also like to relax by participating in my book club and stay active by skiing, dancing, and playing tennis.

My Role at MSK

A breast oncologist is a doctor with special training in breast cancer.

An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.

Areas of Expertise

My Specialties

  • Breast Cancer
  • Early-Phase Clinical Trials
Education & Honors

Education

  • MD, University of Mumbai

Residencies

  • Nuclear Medicine - Radiation Medicine Center/Tata Memorial Hospital
  • Internal Medicine - St. Luke's-Roosevelt Hospital Center/Columbia University

Fellowships

  • Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Jhaveri sees patients at two locations.

Office Phone
Location
New York, NY
300 East 66th Street Floors 1 - 4 New York NY 10065

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Early Drug Development Service doctors

See all Breast Medicine Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Jhaveri K, Juric D, Yap Y, Cresta S, Layman R, Duhoux F, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase 1 study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 2021;27(21):5760-70. PMID: 34433648         

Jhaveri K, Drago J, Shah P, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier M, Sklarin N, Chandarlapaty S, and Modi S A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer. Clin Cancer Res. 2021;27(14):3867-3875. PMID: 33947692

Jhaveri K, dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg J, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy M, Modi S. Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer. JCO Precision Oncology. 2020;4:PO.20.00273. PMCID: PMC7713524

Jhaveri K*, Wang XV, Makker V, Luoh S-W, Mitchell E-P, Zwiebel J-A, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) inpatients with HER2-amplifiedtumors excluding breast and gastric/gastroesophageal junction(GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann of Oncol. 2019;30(11):1821–30. PMCID: PMC6927318  

Jhaveri K, Chang M ,  Juric D,  Saura C,  Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C,  Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2020 Nov 4; clincanres.2657.2020

Publications on PubMed

Visit PubMed for a full listing of Dr. Jhaveri’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Komal Jhaveri discloses the following relationships and financial interests:

  • Aptitude Health
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • AstraZeneca UK Limited
    Professional Services and Activities
  • Blueprint Medicines
    Professional Services and Activities
  • Bristol-Myers Squibb
    Professional Services and Activities
  • Cancer Expert Now, Inc.
    Professional Services and Activities
  • Clinical Education Alliance, LLC
    Professional Services and Activities
  • Curio Science LLC
    Professional Services and Activities
  • Daiichi Sankyo
    Professional Services and Activities
  • EcoR1 Capital LLC
    Professional Services and Activities
  • GE Healthcare
    Professional Services and Activities
  • Genzyme
    Professional Services and Activities
  • Gilead Sciences, Inc.
    Professional Services and Activities
  • Intellisphere, LLC
    Professional Services and Activities
  • Loxo Oncology
    Professional Services and Activities
  • Medscape
    Professional Services and Activities
  • Novartis Pharmaceuticals Corporation
    Professional Services and Activities
  • OncLive
    Professional Services and Activities
  • Oncology Specialty Group
    Professional Services and Activities
  • Physicians' Education Resource
    Professional Services and Activities
  • Plexus Communications
    Professional Services and Activities
  • Rain Therapeutics Inc.
    Professional Services and Activities
  • Roche
    Professional Services and Activities
  • Scorpion Therapeutics, Inc.
    Professional Services and Activities
  • Stemline Therapeutics, Inc.
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures